Trial Profile
Phase II Study of Neoadjuvant Atezolizumab-based Immunotherapy for Patients With Urothelial Carcinoma (NEBULA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NEBULA
- 27 Jan 2024 Results assessing efficacy outcomes and biomarker analysis from phase II trial of escalating doses of neoadjuvant atezolizumab in patients with muscle-invasive urothelial carcinoma ineligible for cisplatin-based chemotherapy presented at the 2024 Genitourinary Cancers Symposium
- 31 May 2023 Status changed from active, no longer recruiting to completed.
- 24 May 2022 Planned End Date changed from 31 Dec 2025 to 31 Mar 2023.